JP2003517267A - Ｈｌａ連鎖子癇前症および流産感受性遺伝子 - Google Patents

Ｈｌａ連鎖子癇前症および流産感受性遺伝子

Info

Publication number
JP2003517267A
JP2003517267A JP2000533590A JP2000533590A JP2003517267A JP 2003517267 A JP2003517267 A JP 2003517267A JP 2000533590 A JP2000533590 A JP 2000533590A JP 2000533590 A JP2000533590 A JP 2000533590A JP 2003517267 A JP2003517267 A JP 2003517267A
Authority
JP
Japan
Prior art keywords
hla
pregnancy
cells
miscarriage
preeclampsia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000533590A
Other languages
English (en)
Japanese (ja)
Inventor
マーガレット オブライエン，
ジョン バーミンガム，
キャスリーン エイ． クワン，
デイビッド エム． ジェンキンス，
トミー ブイ． マッカーシー，
Original Assignee
ナショナル・ユニバーシティ・オブ・アイルランド，コーク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナショナル・ユニバーシティ・オブ・アイルランド，コーク filed Critical ナショナル・ユニバーシティ・オブ・アイルランド，コーク
Publication of JP2003517267A publication Critical patent/JP2003517267A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
JP2000533590A 1998-02-25 1999-02-25 Ｈｌａ連鎖子癇前症および流産感受性遺伝子 Withdrawn JP2003517267A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IE980134 1998-02-25
IE980134 1998-02-25
IE980668 1998-08-12
IE980668 1998-08-12
PCT/IE1999/000012 WO1999043851A1 (fr) 1998-02-25 1999-02-25 Gene de susceptibilite a la pre-eclampsie et aux fausses-couches lie au hla

Publications (1)

Publication Number Publication Date
JP2003517267A true JP2003517267A (ja) 2003-05-27

Family

ID=26320158

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000533590A Withdrawn JP2003517267A (ja) 1998-02-25 1999-02-25 Ｈｌａ連鎖子癇前症および流産感受性遺伝子

Country Status (6)

Country Link
EP (1) EP1056886A1 (fr)
JP (1) JP2003517267A (fr)
AU (2) AU2636399A (fr)
CA (1) CA2321223A1 (fr)
NO (1) NO20004222L (fr)
WO (1) WO1999043851A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010515909A (ja) * 2007-01-11 2010-05-13 ユニヴェルシテ・ドゥ・ラ・メディテラネ 生殖の医学および生物学のためのバイオマーカー
JP2013511708A (ja) * 2009-11-23 2013-04-04 コミッサリア ア レネルジ アトミック エ オー エネルジ アルターネイティブス 骨発生マーカーとしてのｈｌａ−ｇのアイソフォームの使用
JP2016502849A (ja) * 2012-12-19 2016-02-01 アリオサ ダイアグノスティックス インコーポレイテッドＡｒｉｏｓａ Ｄｉａｇｎｏｓｔｉｃｓ，Ｉｎｃ． 卵子提供による妊娠での胎児異数性の非侵襲的検出

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586177B1 (en) * 1999-09-08 2003-07-01 Exact Sciences Corporation Methods for disease detection
ATE313799T1 (de) * 1999-09-27 2006-01-15 Clifford L Librach Nachweis von hla-g
DE19952509A1 (de) * 1999-11-03 2001-05-31 Grosse Wilde Hans Nachweis und Verwendung löslicher HLA-G Moleküle
FR2810047B1 (fr) * 2000-06-13 2004-04-02 Commissariat Energie Atomique Nouvelle isoforme d'hla-g et ses applications
US7191068B2 (en) * 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
WO2005108624A2 (fr) * 2004-05-06 2005-11-17 University Of Chicago, Uctech Utilisation du genotypage hla-g dans des affections d'origine immunologiques
WO2006047787A2 (fr) 2004-10-27 2006-05-04 Exact Sciences Corporation Methode de surveillance de la progression ou la recurrence d'une maladie
WO2006069592A2 (fr) * 2004-12-31 2006-07-06 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Methode permettant de diagnostiquer et/ou de predire la toxemie preeclamptique et/ou des troubles associes
CA3007182A1 (fr) * 2005-03-18 2006-09-21 The Chinese University Of Hong Kong Marqueurs de diagnostic prenatal, de surveillance ou de prediction de lapreeclampsie
WO2007044071A2 (fr) 2005-04-21 2007-04-19 Exact Sciences Corporation Analyse d'echantillons d'acide nucleique heterogenes
US20090156532A1 (en) * 2006-01-24 2009-06-18 The University Of Chicago SNP BINDING SITE FOR microRNAs IN HLA-G
US20090317812A1 (en) * 2006-06-30 2009-12-24 Librach Clifford L Method of detecting preeclampsia
JP2010528629A (ja) 2007-06-07 2010-08-26 シモンズ ハプロミクス リミテッド 遺伝子地図作製及びハプロタイプ決定のための現場（ｉｎｓｉｔｕ）法
GB0804662D0 (en) * 2008-03-13 2008-04-16 Guy S & St Thomas S Nhs Founda Drug response marker
CN104777307B (zh) * 2008-10-31 2019-10-18 耶鲁大学 先兆子痫检测和治疗的方法和组合物
EP3648110A1 (fr) * 2018-11-02 2020-05-06 Immune Compass Ltd. Système de criblage d'un trouble lié au système immunitaire
CA3145620A1 (fr) * 2019-07-05 2021-01-14 Intellexon Gmbh Hla-h en medecine et diagnostic
US20220380848A1 (en) * 2019-10-25 2022-12-01 Intellexon Gmbh Hla class i molecules in in vitro fertilization and further medical implications

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2717498B1 (fr) * 1994-03-18 1996-05-03 Commissariat Energie Atomique Transcrits du gène de CMH de classe I HLA-G et leurs applications.
CA2190576A1 (fr) * 1994-05-18 1995-11-23 Rafik R. Ghobrial Antigenes chimeres de classe i du complexe majeur d'histocompatibilite induisant une tolerance aux allogreffes
JPH11503320A (ja) * 1995-04-07 1999-03-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｈｌａ−ｇ検出用抗体

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010515909A (ja) * 2007-01-11 2010-05-13 ユニヴェルシテ・ドゥ・ラ・メディテラネ 生殖の医学および生物学のためのバイオマーカー
JP2013511708A (ja) * 2009-11-23 2013-04-04 コミッサリア ア レネルジ アトミック エ オー エネルジ アルターネイティブス 骨発生マーカーとしてのｈｌａ−ｇのアイソフォームの使用
JP2016502849A (ja) * 2012-12-19 2016-02-01 アリオサ ダイアグノスティックス インコーポレイテッドＡｒｉｏｓａ Ｄｉａｇｎｏｓｔｉｃｓ，Ｉｎｃ． 卵子提供による妊娠での胎児異数性の非侵襲的検出
JP2019092523A (ja) * 2012-12-19 2019-06-20 アリオサ ダイアグノスティックス インコーポレイテッドＡｒｉｏｓａ Ｄｉａｇｎｏｓｔｉｃｓ，Ｉｎｃ． 卵子提供による妊娠での胎児異数性の非侵襲的検出
JP2021101742A (ja) * 2012-12-19 2021-07-15 アリオサ ダイアグノスティックス インコーポレイテッドＡｒｉｏｓａ Ｄｉａｇｎｏｓｔｉｃｓ，Ｉｎｃ． 卵子提供による妊娠での胎児異数性の非侵襲的検出

Also Published As

Publication number Publication date
AU2636399A (en) 1999-09-15
EP1056886A1 (fr) 2000-12-06
CA2321223A1 (fr) 1999-09-02
WO1999043851A1 (fr) 1999-09-02
AU2003231618A1 (en) 2003-09-11
NO20004222L (no) 2000-10-24
NO20004222D0 (no) 2000-08-23

Similar Documents

Publication Publication Date Title
JP2003517267A (ja) Ｈｌａ連鎖子癇前症および流産感受性遺伝子
Chappell et al. Searching for genetic clues to the causes of pre-eclampsia
Henseler Genetics of psoriasis
Girardi et al. Submicroscopic deletions in the Y chromosome of infertile men.
Hylenius et al. Association between HLA‐G genotype and risk of pre‐eclampsia: a case–control study using family triads
Hviid HLA-G in human reproduction: aspects of genetics, function and pregnancy complications
Hviid et al. Linkage disequilibrium between human leukocyte antigen (HLA) class II and HLA-G—possible implications for human reproduction and autoimmune disease
Vianna et al. Immunogenetics of pregnancy: role of a 14-bp deletion in the maternal HLA-G gene in primiparous pre-eclamptic Brazilian women
Lokki et al. Analysis of complement C3 gene reveals susceptibility to severe preeclampsia
Fritz et al. Low incidence of UPD in spontaneous abortions beyond the 5th gestational week
Hviid HLA-G genotype is associated with fetoplacental growth
Wilczyńska et al. ERAP, KIR and HLA-C gene interaction in susceptibility to recurrent spontaneous abortion in the Polish population
US20080187929A1 (en) Method for determining preeclampsia risk
Takakuwa et al. Possible Susceptibility of the HLA‐DPB1* 0402 and HLA‐DPB1* 04 Alleles to Unexplained Recurrent Abortion: Analysis by means of Polymerase Chain Reaction–Restricted Fragment Length Polymorphism Method
Kanai et al. Polymorphism of human leukocyte antigen‐E gene in the Japanese population with or without recurrent abortion
US8318909B2 (en) Antibodies for diagnosis and treatment of blood platelet alloimmune disorders
Fiorini et al. BTK: 22 novel and 25 recurrent mutations in European patients with X‐linked agammaglobulinemia
TAKAKUWA et al. Significant compatibility does not exist at the HLA‐DQB gene locus in couples with unexplained recurrent abortions
Lokki et al. Role of major histocompatibility complex class III genes in recurrent spontaneous abortions
JP2002512047A (ja) 出生時低体重を予測するための胎児検査
JP6647214B2 (ja) アネキシンａ５ ｍ２ハプロタイプのキャリア状態および産科学のリスク
US7718785B2 (en) Mutations in the SLC40A1 gene associated to impaired iron homeostasis
Laasanen et al. Gamma 2 actin gene (enteric type) polymorphism is not associated with obstetric cholestasis or preeclampsia
Lim et al. CD14 receptor gene promoter polymorphism: awakening maternal immunity during pregnancy
US20090317812A1 (en) Method of detecting preeclampsia

Legal Events

Date Code Title Description
A300 Withdrawal of application because of no request for examination

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20060509